{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:49:47Z","timestamp":1793227787713,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bbalip.2022.159218","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T02:53:12Z","timestamp":1660791192000},"page":"159218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1\/FXR signaling"],"prefix":"10.1016","volume":"1867","author":[{"given":"Silvia","family":"Marchian\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Roselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zampella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Di Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bordoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Urbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva","family":"Morretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fiorucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbalip.2022.159218_bb0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0010","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s10620-016-4143-0","article-title":"Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations","volume":"61","author":"Sherif","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbalip.2022.159218_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.bbalip.2022.159218_bb0025","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.bbalip.2022.159218_bb0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7861\/clinmedicine.7-2-119","article-title":"Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs","volume":"7","author":"Whalley","year":"2007","journal-title":"Clin. Med."},{"key":"10.1016\/j.bbalip.2022.159218_bb0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/nyas.12016","article-title":"Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals","volume":"1281","author":"Masuoka","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbalip.2022.159218_bb0040","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2022.159218_bb0045","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.bbalip.2022.159218_bb0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cld.2017.08.012","article-title":"Current treatment of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"22","author":"Hung","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.bbalip.2022.159218_bb0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.phrs.2018.07.014","article-title":"Future trends in the treatment of non-alcoholic steatohepatitis","volume":"134","author":"Fiorucci","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbalip.2022.159218_bb0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbalip.2022.159218_bb0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile acid metabolism in liver pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"10.1016\/j.bbalip.2022.159218_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2021.101094","article-title":"Bile acids and their receptors in metabolic disorders","volume":"82","author":"Fiorucci","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159218_bb0075","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science (80-.)"},{"key":"10.1016\/j.bbalip.2022.159218_bb0080","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbalip.2022.159218_bb0085","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2022.159218_bb0090","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMct074694","article-title":"Ursodeoxycholic acid for the treatment of primary biliary cirrhosis","volume":"357","author":"Lindor","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2022.159218_bb0095","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-230X-13-140","article-title":"The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review","volume":"13","author":"Xiang","year":"2013","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0100","first-page":"203","article-title":"The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study","volume":"164","author":"Troisi","year":"2013","journal-title":"Clin. Ter."},{"key":"10.1016\/j.bbalip.2022.159218_bb0105","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2022.159218_bb0110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2022.159218_bb0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000454904","article-title":"Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases","volume":"35","author":"Halilbasic","year":"2017","journal-title":"Dig. Dis."},{"key":"10.1016\/j.bbalip.2022.159218_bb0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000371904","article-title":"Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders","volume":"33","author":"Trauner","year":"2015","journal-title":"Dig. Dis."},{"key":"10.1016\/j.bbalip.2022.159218_bb0125","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000454853","article-title":"Therapeutic mechanisms of bile acids and nor-ursodeoxycholic acid in non-alcoholic fatty liver disease","volume":"35","author":"Steinacher","year":"2017","journal-title":"Dig. Dis."},{"key":"10.1016\/j.bbalip.2022.159218_bb0130","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.2337\/db13-0299","article-title":"Dissociation of intestinal and hepatic activities of FXR and LXR\u03b1 supports metabolic effects of terminal ileum interposition in rodents","volume":"62","author":"Mencarelli","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.bbalip.2022.159218_bb0135","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2022.159218_bb0140","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ijc.22808","article-title":"Thermographic assessment of tumor growth in mouse xenografts","volume":"121","author":"Song","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbalip.2022.159218_bb0145","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbalip.2022.159218_bb0150","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1021\/jm500889f","article-title":"Modification on ursodeoxycholic acid (UDCA) scaffold. Discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1)","volume":"57","author":"Sepe","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbalip.2022.159218_bb0155","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbalip.2022.159218_bb0160","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.steroids.2014.02.003","article-title":"Incisterols, highly degraded marine sterols, are a new chemotype of PXR agonists","volume":"83","author":"Chianese","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.bbalip.2022.159218_bb0165","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jm401873d","article-title":"Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors","volume":"57","author":"D\u2019Amore","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbalip.2022.159218_bb0170","first-page":"1422","article-title":"Ursodeoxycholic acid is a GPBAR1 agonist and resets liver\/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH","volume":"2019","author":"Carino","year":"1864","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.bbalip.2022.159218_bb0175","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2022.159218_bb0180","article-title":"Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling","volume":"36","author":"Marchian\u00f2","year":"2022","journal-title":"FASEB J. Off. Publ. Fed. Am. SocExp. Biol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/nu11051132","article-title":"Transcriptome analysis of dual FXR and GPBAR1 agonism in rodent model of NASH reveals modulation of lipid droplets formation","volume":"11","author":"Carino","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.bbalip.2022.159218_bb0190","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbalip.2022.159218_bb0195","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbalip.2022.159218_bb0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5551\/jat.14001","article-title":"Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Huang","year":"2013","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.bbalip.2022.159218_bb0205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0378-1119(00)00518-7","article-title":"Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha)","volume":"262","author":"Chiang","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.bbalip.2022.159218_bb0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0006-291X(02)00229-2","article-title":"LXR alpha is the dominant regulator of CYP7A1 transcription","volume":"293","author":"Gupta","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbalip.2022.159218_bb0215","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbalip.2022.159218_bb0220","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bbalip.2022.159218_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071805","article-title":"Diet-induced models of non-alcoholic fatty liver disease: food for thought on sugar, fat, and cholesterol","volume":"10","author":"Eng","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbalip.2022.159218_bb0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejphar.2017.05.010","article-title":"Animal models of atherosclerosis","volume":"816","author":"Emini Veseli","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmed.2021.10.005","article-title":"Linking liver metabolic and vascular disease via bile acid signaling","volume":"28","author":"Fiorucci","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbalip.2022.159218_bb0240","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1161\/CIRCULATIONAHA.107.704254","article-title":"Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport","volume":"116","author":"Tanigawa","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.bbalip.2022.159218_bb0245","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1194\/jlr.RA119000307","article-title":"Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism","volume":"61","author":"Straniero","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159218_bb0250","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1194\/jlr.RA119000243","article-title":"A human-like bile acid pool induced by deletion of hepatic","volume":"61","author":"de Boer","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159218_bb0255","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159218_bb0260","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbalip.2022.159218_bb0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","article-title":"Bile acid metabolism and signaling in liver disease and therapy","volume":"1","author":"Chiang","year":"2017","journal-title":"Liver Res."},{"key":"10.1016\/j.bbalip.2022.159218_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The pharmacology of bile acids and their receptors","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0280","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X receptor modulators 2014-present: a patent review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opin Ther Pat."},{"issue":"Suppl 1","key":"10.1016\/j.bbalip.2022.159218_bb0295","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S2210-7401(12)70020-7","article-title":"Treatment of NASH with ursodeoxycholic acid: pro","volume":"36","author":"Ratziu","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0300","first-page":"781","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial., lancet","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0305","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s11695-019-03877-6","article-title":"Serum bile acid levels before and after sleeve gastrectomy and their correlation with obesity-related comorbidities","volume":"29","author":"De Vuono","year":"2019","journal-title":"Obes. Surg."},{"key":"10.1016\/j.bbalip.2022.159218_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013238","article-title":"The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice","volume":"5","author":"Mencarelli","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbalip.2022.159218_bb0315","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.bbalip.2022.159218_bb0320","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fendo.2019.00539","article-title":"Potential adiponectin receptor response modifier therapeutics","volume":"10","author":"Otvos","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bbalip.2022.159218_bb0325","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbalip.2022.159218_bb0330","first-page":"192","article-title":"Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: a systematic review","volume":"4","author":"Reardon","year":"2016","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159218_bb0335","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2022.159218_bb0340","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbalip.2022.159218_bb0345","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.105.085597","article-title":"Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis","volume":"315","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbalip.2022.159218_bb0350","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbalip.2022.159218_bb0355","doi-asserted-by":"crossref","first-page":"43290","DOI":"10.1038\/srep43290","article-title":"Hyodeoxycholic acid derivatives as liver X receptor \u03b1 and G-protein-coupled bile acid receptor agonists","volume":"7","author":"De Marino","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2022.159218_bb0360","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cellimm.2017.03.001","article-title":"Role of immune cells in obesity induced low grade inflammation and insulin resistance","volume":"315","author":"Asghar","year":"2017","journal-title":"Cell. Immunol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198122001081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198122001081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:14:40Z","timestamp":1761387280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388198122001081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1388198122001081"],"URL":"https:\/\/doi.org\/10.1016\/j.bbalip.2022.159218","relation":{},"ISSN":["1388-1981"],"issn-type":[{"value":"1388-1981","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1\/FXR signaling","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbalip.2022.159218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"159218"}}